MGO One Seven LLC Has $368,000 Stock Position in Enovis Co. (NYSE:ENOV)

MGO One Seven LLC increased its position in Enovis Co. (NYSE:ENOV) by 22.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 8,390 shares of the company’s stock after acquiring an additional 1,538 shares during the period. MGO One Seven LLC’s holdings in Enovis were worth $368,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Confluence Investment Management LLC acquired a new stake in Enovis in the fourth quarter worth about $3,494,000. UMB Bank n.a. increased its position in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company’s stock worth $677,000 after purchasing an additional 2,518 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Enovis in the fourth quarter worth about $437,000. Finally, Tributary Capital Management LLC grew its position in shares of Enovis by 33.9% during the 4th quarter. Tributary Capital Management LLC now owns 566,089 shares of the company’s stock worth $24,840,000 after buying an additional 143,258 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Trading Down 1.2 %

ENOV opened at $34.67 on Tuesday. The firm’s fifty day moving average is $36.51 and its two-hundred day moving average is $42.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market cap of $1.98 billion, a PE ratio of -15.83 and a beta of 1.86. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $56.43.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Enovis in a research note on Wednesday, April 9th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.